The United States is amid a dangerous drug shortage that endangers patients, undermines our health care system and exposes a deep vulnerability to national security. America’s overwhelming reliance on foreign manufacturers for generic drugs is at the center of it.
In June 2022, the Biden administration introduced a two-year tariff moratorium, temporarily suspending import duties on solar cells and panels from four key Southeast Asian exporting nations—Cambodia, Malaysia, Thailand, and Vietnam.
It’s been five years in the making, yet a bill requiring online retailers to label the country of origin for merchandise remains a tough sell in Congress—even among the lawmakers who introduced it back in 2020.
CPA cautions against adopting a reciprocal tariff strategy aimed primarily at negotiating lower foreign trade barriers and more favorable investment conditions abroad. A reciprocal tariff strategy that prioritizes foreign governments’ willingness to reduce their trade barriers or be more receptive to foreign investment is in conflict with the stated goals of the America First Trade Policy Memorandum and undermines the predictability and stability American businesses need to confidently invest in long-term domestic production.
It took nine months to rescue two astronauts stuck on the International Space Station this weekend, yet somehow President Trump is expected to rewrite global trade rules between the U.S. and 166 World Trade Organization-member countries in less than two months.
In a House Oversight subcommittee hearing on Feb. 26, the Inflation Reduction Act (IRA) was hit with the usual swipes from detractors, with some calling it the “green scam”, but China’s solar company benefits were never mentioned.
CPA announced key leadership changes as CEO Michael Stumo steps down to take on a new role in the Trump administration. Jon Toomey has been elevated as President of CPA to lead the organization and Nick Iacovella has been promoted to Executive Vice President.
For far too long, America has been at the mercy of foreign producers that routinely violate FDA safety regulations for life-saving medicines, generic drugs, and essential medical equipment.
It’s the most well-known secret on Capitol Hill: China owns the American generic drug supply chain. Basic thyroid or blood pressure medications might finally be put into pill form in an Indian lab and sold under an Indian brand like Cipla. But the organic compounds, or key starting materials, mostly come from China.
This long-overdue action will protect American manufacturers and workers from the devastating surge of foreign imports that has harmed U.S. industry, particularly from Mexico in blatant violation of the 2019 Joint Steel and Aluminum Agreement.
Notifications